Somatostatin does not cause sustained fasting hyperglycemia in man

R. Rizza, C. Verdonk, J. Miles, F. J. Service, M. Haymond, J. Gerich

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Somatostatin inhibits both insulin and glucagon secretion; its short-term infusion causes a transient decrease in plasma glucose followed by modest hyperglycemia in man, suggesting that insulin deficiency per se is sufficient to cause fasting hyperglycemia. If this is true, then prolonged inhibition of insulin secretion should result in persistent and more progressive hyperglycemia. On the other hand, if glucagon modifies the metabolic consequences of insulin deficiency, then prolonged inhibition of secretion of both insulin and glucagon might not result in sustained hyperglycemia. To examine these alternatives, changes in plasma glucose, insulin and glucagon, as well as glucose turnover and glucose balance during prolonged infusions of somatostatin (for 12 hr) were studied.

Original languageEnglish (US)
Pages (from-to)643-644
Number of pages2
JournalHormone and Metabolic Research
Volume11
Issue number11
StatePublished - 1979

Fingerprint

Somatostatin
Hyperglycemia
Fasting
Insulin
Glucagon
Glucose
Plasmas

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Rizza, R., Verdonk, C., Miles, J., Service, F. J., Haymond, M., & Gerich, J. (1979). Somatostatin does not cause sustained fasting hyperglycemia in man. Hormone and Metabolic Research, 11(11), 643-644.

Somatostatin does not cause sustained fasting hyperglycemia in man. / Rizza, R.; Verdonk, C.; Miles, J.; Service, F. J.; Haymond, M.; Gerich, J.

In: Hormone and Metabolic Research, Vol. 11, No. 11, 1979, p. 643-644.

Research output: Contribution to journalArticle

Rizza, R, Verdonk, C, Miles, J, Service, FJ, Haymond, M & Gerich, J 1979, 'Somatostatin does not cause sustained fasting hyperglycemia in man', Hormone and Metabolic Research, vol. 11, no. 11, pp. 643-644.
Rizza R, Verdonk C, Miles J, Service FJ, Haymond M, Gerich J. Somatostatin does not cause sustained fasting hyperglycemia in man. Hormone and Metabolic Research. 1979;11(11):643-644.
Rizza, R. ; Verdonk, C. ; Miles, J. ; Service, F. J. ; Haymond, M. ; Gerich, J. / Somatostatin does not cause sustained fasting hyperglycemia in man. In: Hormone and Metabolic Research. 1979 ; Vol. 11, No. 11. pp. 643-644.
@article{42eef0f879014533b53a2896b60f7cb6,
title = "Somatostatin does not cause sustained fasting hyperglycemia in man",
abstract = "Somatostatin inhibits both insulin and glucagon secretion; its short-term infusion causes a transient decrease in plasma glucose followed by modest hyperglycemia in man, suggesting that insulin deficiency per se is sufficient to cause fasting hyperglycemia. If this is true, then prolonged inhibition of insulin secretion should result in persistent and more progressive hyperglycemia. On the other hand, if glucagon modifies the metabolic consequences of insulin deficiency, then prolonged inhibition of secretion of both insulin and glucagon might not result in sustained hyperglycemia. To examine these alternatives, changes in plasma glucose, insulin and glucagon, as well as glucose turnover and glucose balance during prolonged infusions of somatostatin (for 12 hr) were studied.",
author = "R. Rizza and C. Verdonk and J. Miles and Service, {F. J.} and M. Haymond and J. Gerich",
year = "1979",
language = "English (US)",
volume = "11",
pages = "643--644",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "11",

}

TY - JOUR

T1 - Somatostatin does not cause sustained fasting hyperglycemia in man

AU - Rizza, R.

AU - Verdonk, C.

AU - Miles, J.

AU - Service, F. J.

AU - Haymond, M.

AU - Gerich, J.

PY - 1979

Y1 - 1979

N2 - Somatostatin inhibits both insulin and glucagon secretion; its short-term infusion causes a transient decrease in plasma glucose followed by modest hyperglycemia in man, suggesting that insulin deficiency per se is sufficient to cause fasting hyperglycemia. If this is true, then prolonged inhibition of insulin secretion should result in persistent and more progressive hyperglycemia. On the other hand, if glucagon modifies the metabolic consequences of insulin deficiency, then prolonged inhibition of secretion of both insulin and glucagon might not result in sustained hyperglycemia. To examine these alternatives, changes in plasma glucose, insulin and glucagon, as well as glucose turnover and glucose balance during prolonged infusions of somatostatin (for 12 hr) were studied.

AB - Somatostatin inhibits both insulin and glucagon secretion; its short-term infusion causes a transient decrease in plasma glucose followed by modest hyperglycemia in man, suggesting that insulin deficiency per se is sufficient to cause fasting hyperglycemia. If this is true, then prolonged inhibition of insulin secretion should result in persistent and more progressive hyperglycemia. On the other hand, if glucagon modifies the metabolic consequences of insulin deficiency, then prolonged inhibition of secretion of both insulin and glucagon might not result in sustained hyperglycemia. To examine these alternatives, changes in plasma glucose, insulin and glucagon, as well as glucose turnover and glucose balance during prolonged infusions of somatostatin (for 12 hr) were studied.

UR - http://www.scopus.com/inward/record.url?scp=0018634206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018634206&partnerID=8YFLogxK

M3 - Article

C2 - 395056

AN - SCOPUS:0018634206

VL - 11

SP - 643

EP - 644

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 11

ER -